Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergTrump DEI Purge Hits ...

ECIM 2025 saw a heated discussion on whether anticoagulation in DVT should be treated like a chronic condition, as new ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

The Maryland Senate voted to allow a state board to extend its mandate for lowering prescription drug costs to all residents.

PARIS] Ozempic-maker Novo Nordisk is planning to make more of its medicines for the US market in the country; Boeing risks a ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.